Why Genflow
Founded in 2020, Genflow Biosciences plc is an emerging leader in the field of longevity research with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives. Genflow Biosciences’ lead compound, GF-1002 operates through the delivery of a centenarian variant of the SIRT6 gene. This gene, identified in individuals who reach the age of 100 or beyond, has demonstrated promising preclinical results.
Extending Healthspan and Lifespan with Groundbreaking Science
Genflow Biosciences is focused on developing and commercializing innovative therapies that target the aging process in both humans and dogs. Our goal is to halt or delay the onset of aging, which will lower healthcare expenditures and ease the emotional and social challenges associated with an aging population by directly intervening in the process.
Genflow Meets Primary Endpoint in SLAB Clinical Trial
Detailed Trial Results to be Presented at the Animal Longevity Summit 2026
Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) (“Genflow” or the “Company”), a biotechnology company focused on the development of gene therapies for age-related diseases, announces that its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial, evaluating its proprietary SIRT6 centenarian gene therapy in aged dogs, has met its primary endpoint. The Company further announces that detailed results from the completed trial will be presented at the Animal Longevity Summit (“ALOS”) in Toronto, Canada, on 1–2 October 2026.
